THRIVE-132: Therapy for Reduction in VOC Readmissions with Inclacumab
Patient-friendly certified
What is this?
About the study
fsdsd To identify treatments that do not rely only on opioids or other medications. Participants will use their smartphone to answer questionnaires and interact with a mobile application. To identify treatments that do not rely only on opioids or other medications. Participants will use their smartphone to answer questionnaires and interact with a mobile application. To identify treatments that do not rely only on opioids or other medications. Participants will use their smartphone to answer questionnaires and interact with a mobile application.
Read moreParticipation information
Locations
2 United States sites
1 Canada site
1 Turkey site
Age
18 - 28 years
Gender
All
Genotypes
Hb SC
Hb Sβ0 thalassemia
Hb Sβ+ thalassemia
Hb SD
Study Information
Study type
Survey
Interventions
c-CBT, m-Education
Phase
Phase 2
Compensation
test
Am I Eligible
Requirements
You may be eligible to participate in this study if you:- People with any type of sickle cell disease
- Male or female, age 18 years or older
- Reports chronic pain: i.e pain more days than not for the past 3 months or longer and/or is prescribed daily or long-acting opioids for pain.
- English speaking
Restrictions
You can't participate in this study if you:- Any potential participants who fail consent comprehension questions
Study point of contact
| Charles Jonassaint, PhD, MHS | |
| 412-586-9850 | |
| cjonassaint@pitt.edu |